Merck's pneumococcal vaccine suffers PDUFA delay in pediatric population, with Pfizer hot on its tail
Back in July, Merck’s pneumococcal vaccine Vaxneuvance got the seal of approval from the FDA to treat adults, with analysts predicting it could be a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.